Low-Code LIMS Boosts Lab Automation

Low-code LIMS cuts lab setup time by up to ⁦70%⁩

Clinisys announced a partnership with Decisions to deliver a low‑code / no‑code configuration layer for its LIMS/LIS platforms, letting labs build custom workflows without writing a single line of code. The joint solution promises to dramatically reduce the time needed to launch new tests, a claim echoed by both companies in their press release.

How the low‑code engine works

The new configuration layer sits on top of Clinisys’s existing LIMS/LIS core and exposes drag‑and‑drop modules for sample tracking, result reporting, and instrument integration. Because the modules are pre‑built, lab staff can assemble a workflow by linking blocks together, much like building a flow in a visual automation tool. Decisions supplies the no‑code front‑end, while Clinisys provides the laboratory‑grade data model and compliance features. According to the announcement, the approach reduces the need for bespoke software development, which traditionally consumes a sizable portion of a lab’s IT budget.

Why low‑code matters for small labs and biotech startups

Small‑business labs often lack dedicated IT teams, so every hour spent on custom coding is a direct hit to their bottom line. By moving to a visual builder, labs can re‑allocate staff to higher‑value activities such as assay development or client support. The partnership also aligns with broader trends in AI for business and marketing automation, where low‑code platforms enable rapid experimentation without heavy engineering overhead.

Israeli perspective: what the savings look like

Using the typical Israeli automation figures, a lab that spends about 10 hours / week on manual sample entry could automate a large share of that task. A medium‑complexity build costs roughly ₪4,500 per weekly hour, so automating those 10 hours would require an upfront investment of around ₪45,000. This illustrates how low‑code LIMS can turn a modest software spend into a rapid ROI for Israeli labs.

What it means for Israel’s AI‑automation ecosystem

Israel’s Innovation Authority has been championing low‑code tools as a way to accelerate digital transformation in life‑science companies. The Clinisys‑Decisions deal showcases a model that Israeli startups can emulate: combine a domain‑specific core (LIMS) with a no‑code front‑end to serve niche markets quickly. For local labs, the ability to launch new tests without a full‑time developer team dovetails with the country’s strong CRM for small businesses and WhatsApp for business adoption, where integration via APIs is already commonplace.

Looking ahead: integration with chatbots and CRM

Both partners hinted at future extensions that will let labs embed chatbot for business interfaces directly into the LIMS, enabling technicians to query sample status via WhatsApp or a web chat. Such integration would close the loop between the lab’s data engine and front‑office CRM systems, further reducing manual hand‑offs and supporting end‑to‑end automation.

Bottom line

Clinisys’s low‑code LIMS/LIS configuration, powered by Decisions, promises dramatic speed‑ups for laboratory workflow creation, a clear cost advantage for small labs, and a fast payback in the Israeli market. As more labs adopt visual automation, the ripple effect will likely boost related AI‑driven tools across the small business automation landscape.

What it means for Israel

For Israeli labs, the combination of a modest upfront cost and a rapid return makes low‑code LIMS an attractive investment. It also aligns with national goals to expand AI‑enabled automation across SMEs. Interested readers can explore our automation ROI calculator and browse the latest AI‑automation benchmarks on our data page.

Sources & further reading

• Original source: Google News — nocode